Sell Call on SLS Due to Failing Drug and Delayed Clinical Updates
-18.22%current return
"I do think SLS will fail. I can't believe the stock's at five. I may have to get involved here. SLS is crazy. Oh, it's a 400% bar rate. Another special capper special. Please sell everything on SLS ASAP. this drug does not work and they're der they're not they're there haven't reported the study in years it's taking forever no redue tide is just intense I don't think so."
The speaker delivers a strong sell recommendation on SLS, arguing that the company's drug is not effective and its clinical study updates are excessively delayed. The low trading price, mentioned at five dollars, further intensifies the bearish sentiment, prompting immediate divestment.
Target:N/A
Horizon:Expires Jan 25, 2026 High ConvictionScore: 8.0
Stock Idea •The Shkreli Pill • Jan 7, 2026